Exploration of Targeted Anti-tumor Therapy

Table 1. Suspended, active non-recruiting and recruiting oncological clinical trials throughout the World (W), the United States (U) and Italy (I) from the beginning of pandemic to the first six months of 2022

Study status	30/01/2020 to 30/07/2020			01/08/2020 to 31/12/2020			01/01/2021 to 30/06/2021			01/07/2021 to 31/12/2021			01/01/2022 to 30/06/2022
Study status	W	U	I	W	U	I	W	U	I	W	U	I	W	U	I
Suspended	28	18	1	14	11	/	20	17	/	16	14	/	16	11	/
Active, non-recruiting	302	155	37	259	138	28	250	116	30	162	69	18	92	39	3
Recruiting	1,421	577	100	1,723	703	117	2,511	945	169	2,401	960	143	2,362	932	113
Total	3,364	1,160	220	3,394	1,220	225	4,335	1,439	291	3,959	1,407	228	4,006	1,290	208

Return to article view

The 30/01/2020 means January 30th, 2020; other dates are in the same format. /: not applicable

Declarations

Author contributions

RB and ZB: Conceptualization. ZB, AL, MB, and VA: Methodology. VA, GR, VT, LM, and CC: Data curation. VA and ZB: Writing—original draft, Writing—review & editing. RB: Supervision. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

RB is a consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli-Lilly, Roche, Amgen, GSK, Eisai, Bristol Myers Squibb. ZB is a consultant/advisory board member for Daichii Sanchyo. All other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Coronavirus disease (COVID-19) pandemic [Internet]. Switzerland: WHO; c2023 [cited 2022 Jun 15] Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/

COVID-19 overview and infection prevention and control priorities in non-U.S. healthcare settings [Internet]. Source: Centers for Disease Control and Prevention; [cited 2022 Jun 15]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/overview/index.html/

North CM, Dougan ML, Sacks CA. Improving clinical trial enrollment—in the Covid-19 era and beyond. N Engl J Med. 2020;383:1406–8. [DOI] [PubMed]

Ndumele A, Park KU. The impact of COVID-19 on national clinical trials network breast cancer trials. Curr Breast Cancer Rep. 2021;13:103–9. [DOI] [PubMed] [PMC]

Ballatore Z, Merloni F, Ranallo N, Bastianelli L, Vitarelli F, Cantini L, et al. Cancer patient perspective in the arena of COVID-19 pandemic. Psychooncology. 2022;31:39–45. [DOI] [PubMed] [PMC]

de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Laarhoven HWM, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective. Eur J Cancer. 2020;136:132–9. [DOI] [PubMed] [PMC]

Al-Quteimat OM, Amer AM. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43:452–5. [DOI] [PubMed] [PMC]

Apisarnthanarak A, Siripraparat C, Apisarnthanarak P, Ullman M, Saengaram P, Leeprechanon N, et al. Patients’ anxiety, fear, and panic related to coronavirus disease 2019 (COVID-19) and confidence in hospital infection control policy in outpatient departments: a survey from four Thai hospitals. Infect Control Hosp Epidemiol. 2021;42:1288–90. [DOI] [PubMed] [PMC]

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91. [DOI] [PubMed] [PMC]

10.

Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–98. [DOI] [PubMed] [PMC]

11.

Guidance for NIH-funded clinical trials and human subjects studies affected by COVID-19 [Internet]. Source: National Institutes of Health (NIH); [cited 2022 Jul 5]. Available from: https://nexus.od.nih.gov/all/2020/03/17/guidance-for-nih-funded-clinical-trials-and-human-subjects-studies-affected-by-covid-19/

12.

Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards [Internet]. [Cited 2022 Jul 5]. Available from: https://collections.nlm.nih.gov/catalog/nlm:nlmuid-9918351277706676-pdf/

13.

van Dorn A. COVID-19 and readjusting clinical trials. Lancet. 2020;396:523–4. [DOI] [PubMed] [PMC]

14.

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic [Internet]. European Medicines Agency; c1995–2023 [cited 2022 Jul 5]. Available from: https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemic

15.

Clinical trials’ management in Italy during the COVID-19 (coronavirus disease 19) emergency [Internet]. [Cited 2022 Jul 5]. Available from: https://www.aifa.gov.it/documents/20142/871583/Comunicato_gestione_studi_clinici_in_emergenza_COVID-19_EN_12.03.2020.pdf

16.

Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open. 2020;3:e2010651. [DOI] [PubMed] [PMC]

17.

NCTN group chairs: cancer trials take backseat to clinical care amid COVID-19 pandemic [Internet]. The Cancer Letter Inc.; c2023 [cited 2022 Jul 5]. Available from: https://cancerletter.com/articles/20200410_1/

18.

Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov. 2020;19:376–7. [DOI] [PubMed]

19.

Patil R, Varner C. Delivering clinical trial continuity during COVID-19. IQVIA; 2020.

20.

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al.; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18. Erratum in: Lancet. 2020;396:758. [DOI] [PubMed] [PMC]

21.

ClinicalTrials.gov [Internet]. [Cited 2022 Jul 8]. Available from: https://clinicaltrials.gov/ct2/search/advanced?cond=&term=&cntry=&state=&city=&dist=

22.

Agostinelli V, De Filippis C, Torniai M, Rocchi MBL, Pagliacci A, Ricci G, et al. Primum non nocere: how to ensure continuity of care and prevent cancer patients from being overlooked during the COVID-19 pandemic. Cancer Med. 2023;12:1821–8. [DOI] [PubMed] [PMC]

23.

Hall E, Lewis R, Snowdon C. Life after COVID-19 for cancer clinical trials. Int J Radiat Oncol Biol Phys. 2020;108:486–8. [DOI] [PubMed] [PMC]

24.

Fontana E, Arkenau HT. Oncology clinical trials during the COVID-19 outbreak: lessons learnt during the crisis and future opportunities. Cancer Treat Rev. 2020;88:102047. [DOI] [PubMed] [PMC]

25.

Caldarella C, Cocciolillo F, Taralli S, Lorusso M, Scolozzi V, Pizzuto DA, et al. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study. Eur J Nucl Med Mol Imaging. 2022;49:1623–9. [DOI] [PubMed] [PMC]

26.

Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, et al. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020;16:417–21. [DOI] [PubMed]

27.

Tolaney SM, Lydon CA, Li T, Dai J, Standring A, Legor KA, et al. The impact of COVID-19 on clinical trial execution at the Dana-Farber cancer institute. J Natl Cancer Inst. 2021;113:1453–9. [DOI] [PubMed] [PMC]

28.

Perez-Gracia JL, Awada A, Calvo E, Amaral T, Arkenau HT, Gruenwald V, et al. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open. 2020;5:e000662. [DOI] [PubMed] [PMC]

29.

Gregucci F, Caliandro M, Surgo A, Carbonara R, Bonaparte I, Fiorentino A. Cancer patients in Covid-19 era: swimming against the tide. Radiother Oncol. 2020;149:109–10. [DOI] [PubMed] [PMC]

30.

Massari F, Mollica V, Salvagni S, Tognetto M, Ardizzoni A. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care. Future Oncol. 2020;16:1413–5. [DOI] [PubMed] [PMC]

31.

Asaad M, Habibullah NK, Butler CE. The impact of COVID-19 on clinical trials. Ann Surg. 2020;272:e222–3. [DOI] [PubMed] [PMC]

32.

Nabhan C, Choueiri TK, Mato AR. Rethinking clinical trials reform during the COVID-19 pandemic. JAMA Oncol. 2020;6:1327–9. [DOI] [PubMed]

33.

Tella SH, Kommalapati A, Alberts SR, McWilliams R, Mahipal A. Collateral damage of COVID-19 pandemic on oncology clinical trials. Chin Clin Oncol. 2020;9:80. [DOI] [PubMed]

34.

Wosik J, Fudim M, Cameron B, Gellad ZF, Cho A, Phinney D, et al. Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc. 2020;27:957–62. [DOI] [PubMed] [PMC]

35.

Mooney M, McCaskill-Stevens W. Interim guidance for patients on clinical trials supported by the NCI cancer therapy evaluation program and the NCI community oncology research program; 2020.

36.

Gensheimer MF, Yom SS, Soto N, Dignam JJ, Le QT, Machtay M, et al. Multicenter clinical cancer research after COVID-19: a perspective from NRG oncology. Int J Radiat Oncol Biol Phys. 2020;108:483–5. [DOI] [PubMed] [PMC]

37.

de Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, et al. Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months. Oncol Ther. 2020;8:171–82. [DOI] [PubMed] [PMC]

38.

Sharpless NE. COVID-19 and cancer. Science. 2020;368:1290. [DOI] [PubMed]